JTJun Teruya

Jun Teruya

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jun Teruya has a total of 149 co-authors. Here are the top co-authors by number of shared publications:

  • Vadim Kostousov

    Department of Pathology & Immunology, Texas Children's Hospital, Baylor College of Medicine, 6621 Fannin Street, Suite WB 1100, Houston, TX 77030, USA

    13 shared publications
  • Lisa Hensch

    Department of Pathology and Immunology Baylor College of Medicine, Texas Children's Hospital Houston Texas USA

    11 shared publications
  • Shiu-Ki Rocky Hui

    Department of Pathology & Immunology, Texas Children's Hospital and Baylor College of Medicine, Houston, Texas

    8 shared publications
  • Karen Bruzdoski

    Division of Transfusion Medicine & Coagulation, Department of Pathology, Texas Children’s Hospital, Baylor College of Medicine, Houston, Texas

    7 shared publications
  • Karin Anneliese Fox

    University of Texas Medical Branch in Galveston Houston Texas USA

    6 shared publications
  • Alireza Shamshirsaz

    Fetal Care and Surgery Center, Division of Fetal Medicine and Surgery, Boston Children's Hospital Harvard Medical School Boston Massachusetts USA

    4 shared publications

Latest Publications

  • Open Access

    Assessment of Thrombin Generation in Pediatric Patients on Extracorporeal Life Support: Impact of Bivalirudin and Other Anticoagulants

    by Vadim Kostousov, Karen Bruzdoski, Amir Navaei, Jun Teruya

    Introduction: Bivalirudin is an alternative anticoagulant to heparin and is widely used in pediatric extracorporeal life support (ECLS). Its activity is monitored using activated partial thromboplastin time (aPTT) and/or more specific tests such as plasma‐diluted thrombin time (dTT). A new automated thrombin generation assay (TGA) has also shown promise in evaluating the hemostatic response in anticoagulated patients; however, its utility for monitoring bivalirudin or other anticoagulants in pediatrics remains unknown. We aimed to evaluate TGA in pediatric patients treated with bivalirudin and to compare it with that observed in patients receiving other commonly used anticoagulants. Methods: TGA, aPTT, aPTT with hepzyme, dTT, INR were measured in 30 specimens from 12 pediatric ECLS patients anticoagulated with bivalirudin. In addition, TGA, anti‐Xa assay, and INR were measured in samples from children receiving enoxaparin ( n = 22, 10 patients), heparin ( n = 16, 8 patients), and warfarin ( n = 19, 6 patients). Results: TGA lag ratio showed a strong correlation with bivalirudin concentration as measured by dTT and ROC analysis demonstrated that a Lag ratio > 2.0 predicted specimens within the therapeutic range for bivalirudin (sensitivity 0.88, specificity 0.67, accuracy 0.79). Interestingly, samples containing endogenous heparin‐like substances exhibited paradoxically enhanced thrombin generation, despite having the highest aPTT values. Enoxaparin effect was associated with a reduction in thrombin peak and endogenous thrombin potential (ETP) suppression, while both heparin and warfarin led to a prolonged lag time, along with decreased peak and greater ETP suppression. Conclusion: TGA shows promise in evaluating bivalirudin anticoagulation and is capable of detecting anticoagulant activity across both subtherapeutic and therapeutic levels of other agents commonly used in pediatric patients.

  • Blood Coagulation Analysis in Pediatric Patients on Extracorporeal Life Support with Small-Volume Acoustic Tweezing Thromboelastometry

    by Elizabeth M. Cummins, Karen Bruzdoski, Vadim V. Kostousov, Jun Teruya, Damir B. Khismatullin

    Blood coagulation analysis is essential for evaluating bleeding and clotting risks, particularly in extracorporeal life support (ECLS) patients receiving preventative anticoagulant therapy, like heparin or bivalirudin. Therapy management requires continuous monitoring; however, existing methods exhibit high variability and require relatively large blood volumes, limiting their use in neonatal and pediatric care. This study assesses the ability of integrated quasistatic acoustic tweezing thromboelastometry (i-QATT), a novel noncontact technique utilizing small blood samples (6 µl), to monitor anticoagulant therapy. Integrated quasistatic acoustic tweezing thromboelastometry analysis was conducted on platelet-poor plasma samples collected from pediatric ECLS patients treated with unfractionated heparin (UFH) or bivalirudin, while heparinase was applied to neutralize the anticoagulation effect of UFH. Integrated quasistatic acoustic tweezing thromboelastometry accurately detected UFH and bivalirudin effects and UFH reversal in commercial and patient plasma samples, where clot initiation time, clotting time, and time to firm clot formation were identified as key i-QATT parameters in anticoagulant monitoring. The technique demonstrated sensitivity to anticoagulant dosage levels, effectively distinguished between different anticoagulants, and exhibited strong correlations with gold-standard plasma coagulation tests and rotational thromboelastometry. Additionally, i-QATT showed potential in assessing dynamic changes in thrombosis during the treatment period. The findings of this study highlight i-QATT’s ability to monitor anticoagulant therapy in pediatric patients.

  • Open Access

    Extended-phase anticoagulation for pediatric venous thromboembolism after EINSTEIN Jr

    by Nathan Wilken, Jun Teruya

    Extended-phase anticoagulation for pediatric venous thromboembolism after EINSTEIN Jr

  • Factor XIII Concentrate Mitigates Hemorrhage in Pediatric Extracorporeal Membrane Oxygenation Support With Acquired Factor XIII Deficiency

    by Jun Fujita, Ashish A. Ankola, Arun Saini, Blessy Philip, Derek Danner, Amir Navaei, Vadim Kostousov, Jun Teruya

    Bleeding is a major complication in patients on extracorporeal membrane oxygenation (ECMO). Acquired factor XIII (FXIII) deficiency develops during ECMO support; however, little is known about the effects of FXIII administration on bleeding ECMO outcomes. Our study aimed to evaluate the effect of FXIII concentrate on bleeding during ECMO and suggest an FXIII threshold level. Retrospective review of pediatric ECMO patients who received FXIII infusion. The International Society on Thrombosis and Hemostasis (ISTH) bleeding definition was used to classify bleeding as none (0), minor (1), clinically relevant non-major (2), and major (3). Factor XIII levels and bleeding scores were compared pre- and post-FXIII concentrate. Twenty patients received 27 infusions of FXIII. Factor XIII concentrate dosing was 37 ± 8 units/kg. Factor XIII levels increased from 41% (interquartile range [IQR]: 37–46) to 68% (IQR: 57–82), p value of less than 0.001. Bleeding severity improved after FXIII infusion; the mean ISTH bleeding score decreased from 2.0 ± 0.7 to 0.8 ± 0.9, p value of less than 0.001. Sixteen patients were successfully off ECMO and survived to discharge. Factor XIII administration was associated with improvement in bleeding severity when the initial FXIII level value was less than 50%. Pediatric ECMO patients with persistent bleeding should have FXIII levels measured and consideration of FXIII administration should be made at FXIII level value of less than 50%.


  • Open Access

    Is it time to switch to bivalirudin for ECMO anticoagulation?

    by Amir Navaei, Vadim Kostousov, Jun Teruya

    For decades, unfractionated heparin (hereafter, heparin) has been the primary anticoagulant used for extracorporeal membrane oxygenation (ECMO) support. More recently, however, bivalirudin, a direct thrombin inhibitor, has emerged as an alternative. This systematic review based on PRISMA guidelines, aims to summarize 16 comparative studies and 8 meta-analysis and review articles published from January, 2011 till May, 2023 which directly compares ECMO courses using heparin versus bivalirudin as the anticoagulant. While this comparison is complicated by the lack of a standardized definition of major bleeding or thrombosis, our overall findings suggest there is no statistical difference between heparin and bivalirudin in incidence of bleeding and thrombosis. That said, some studies found a statistical significance favoring bivalirudin in reducing major bleeding, thrombosis, and the need for transfusions. We also offer essential guidance for appropriately selecting an anticoagulant and monitoring its effect in ECMO settings.


  • Open Access

    Editorial: Hemostasis in ECMO and VAD, volume II

    by Jun Teruya, Jean M. Connors, Barbara Zieger

    Editorial: Hemostasis in ECMO and VAD, volume II

  • The History of Extracorporeal Membrane Oxygenation and the Development of Extracorporeal Membrane Oxygenation Anticoagulation

    by Robert Bartlett, Deepa J. Arachichilage, Meera Chitlur, Shiu-Ki Rocky Hui, Cindy Neunert, Andrew Doyle, Andrew Retter, Beverley J. Hunt, Hoong Sern Lim, Arun Saini, et al.

    Extracorporeal membrane oxygenation (ECMO) was first started for humans in early 1970s by Robert Bartlett. Since its inception, there have been numerous challenges with extracorporeal circulation, such as coagulation and platelet activation, followed by consumption of coagulation factors and platelets, and biocompatibility of tubing, pump, and oxygenator. Unfractionated heparin (heparin hereafter) has historically been the defacto anticoagulant until recently. Also, coagulation monitoring was mainly based on bedside activated clotting time and activated partial thromboplastin time. In the past 50 years, the technology of ECMO has advanced tremendously, and thus, the survival rate has improved significantly. The indication for ECMO has also expanded. Among these are clinical conditions such as postcardiopulmonary bypass, sepsis, ECMO cardiopulmonary resuscitation, and even severe coronavirus disease 2019 (COVID-19). Not surprisingly, the number of ECMO cases has increased according to the Extracorporeal Life Support Organization Registry and prolonged ECMO support has become more prevalent. It is not uncommon for patients with COVID-19 to be on ECMO support for more than 1 year until recovery or lung transplant. With that being said, complications of bleeding, thrombosis, clot formation in the circuit, and intravascular hemolysis still remain and continue to be major challenges. Here, several clinical ECMO experts, including the “Father of ECMO”—Dr. Robert Bartlett, describe the history and advances of ECMO.


  • Blood transfusion is associated with increased mortality for neonates with congenital diaphragmatic hernia on extracorporeal membrane oxygenation support

    by Yu Yang, Sharada H. Gowda, Joseph L. Hagan, Lisa Hensch, Jun Teruya, Caraciolo J. Fernandes, Shiu‐Ki R. Hui

    Background and Objectives: Blood transfusion is frequently needed to maintain adequate haemostasis and improve oxygenation for patients treated with extracorporeal membrane oxygenation (ECMO). It is more so for neonates with immature coagulation systems who require surgical intervention such as congenital diaphragmatic hernia (CDH) repair. There is growing evidence suggesting an association between blood transfusions and increased mortality. The aim of this study is to evaluate the association of blood transfusions during the peri‐operative period of CDH repair, among other clinical parameters, with mortality in neonates undergoing on‐ECMO CDH repair.Materials and Methods: We performed a single centre retrospective chart review of all neonates with CDH undergoing on‐ECMO surgical repair from January 2010 to December 2020. Logistic regression was used to investigate associations with survival status.Results: Sixty‐two patients met the inclusion criteria. Platelet transfusions (odds ratio [OR] 1.42, 95% confidence interval [CI]: 1.06–1.90) in the post‐operative period and ECMO duration (OR 1.17, 95% CI: 1.05–1.30) were associated with increased mortality. Major bleeding complications had the strongest association with mortality (OR 10.98, 95% CI: 3.27–36.91). Gestational age, birth weight, Apgar scores, sex, blood type, right versus left CDH, venovenous versus venoarterial ECMO and duration of ECMO before CDH repair and circuit change after adjusting for ECMO duration were not significantly associated with survival.Conclusion: Platelet transfusion in the post‐operative period and major bleeding are associated with increased mortality in CDH neonates with surgical repair. The data suggest a need to develop robust plans for monitoring and preventing coagulation aberrancies during neonatal ECMO support.